Roche diabetes drug taspoglutide has hit its targets, with the pharmaceutical company claiming that Phase III clinical trials have met their primary endpoints according to most recent studies.
The Swiss diabetes drug manufacturer Roche Holding AG reportedly said on Wednesday that a diabetes treatment currently undergoing Phase III clinical trials had been a success. Roche licensed the drug from French drugmaker Ipsen in 2006 after it showed a superior reduction of HbA1c levels.
How the diabetes drug comes to market depends on final reports of its efficiency, and approval by the drug regulators around the world. A number of pharmaceutical companies are thought to have diabetes drugs currently in the pipeline.
Roche diabetes drug hits targets
Wed, 02 Dec 2009
Recommended links
Diabetes forumDiabetes chat
What's new on the site
Diabetes charities
Diabetes alert ID wristband
Diabetes pensions and annuities
The Diet Plate for People with Diabetes
New type 1 diabetes drug
Diabetes drug warning has doctors on alert
Label change for type 2 diabetes drug
Diabetes prevention using diet, not drugs
Diabetes drug better for weight loss
Diabetes drug may have pancreatitis risk
Denial over diabetes drug link
Heart risk not alleviated by diabetes drugs
Obesity increases diabetes drug bill
Med diet could delay diabetes drugs
Diabetes drug prescriptions must stop, study says
Stop prescribing diabetes drug, scientists say
New diabetes drug same price
Dementia drug risk amongst people with diabetes
Iron binding drug could help diabetes neuropathy
Diabetes drug cleared of cancer risk
Canada reviews diabetes drug
Diabetes drug review causes share climb
Sanofi maintain diabetes drug no riskier than insulin
Diabetes drug cleared for European market
Drug association encourages use of diabetes drug
Diabetes drug requires more research, FDA rule
Takeda diabetes drug setback
Diabetes drug reaching stage three trials
Study confirms how diabetes drugs can increase heart risk
Join us